Tirzepatide → Acute kidney injury — Null result

← All findings ⬇ Download signed audit packet

Ledger entry · null-result

Tirzepatide → Acute kidney injury — Null result

Drug: tirzepatide · AE: Acute kidney injury

Caliper validation of the submitted claim (drug=tirzepatide, AE=Acute kidney injury). BELOW_PRR_THRESHOLD — disproportionality not significant (PRR=0.34, lower CI=0.27)

Disproportionality

PRR: 0.34418707628811285 (95% CI 0.27–0.44)
Yates χ²: 82.38764125290685
Cases (case-drug + AE): n = 66
Verdict: BELOW_PRR_THRESHOLD — disproportionality not significant (PRR=0.34, lower CI=0.27)

Top reactions in cohort

MedDRA PT	n
Acute kidney injury	64
Dehydration	23
Diarrhoea	10
Vomiting	10
Nausea	7
Off label use	7
Septic shock	4
Weight decreased	4

Source: openFDA FAERS, Caliper Engine v0. Pre-registration sha1 locked at submission time; ledger entry signed with platform Ed25519 key.

Independent Verification & Validation

Every finding includes an in-engine adversary review at no cost. For findings you plan to cite in a regulatory submission, scientific publication, or board-grade decision, we offer an additional layer of independent, audit-grade verification — reviewed by an externally-trained system that has never seen your data, your training corpus, or our hardware, and cryptographically signed.

Reference: d3cb673fca101e4a9313adac7feb24ea98aed23d